Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

November 15, 2024

Opinion

Video

Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.

EP: 1.An Overview of HER2 Alterations in NSCLC and Implications for Treatment

Now Viewing

EP: 2.Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

EP: 3.T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights

EP: 4.ADCs, TKIs, and the Evolving Treatment Landscape in HER2-Altered NSCLC

EP: 5.AE Monitoring and Management With Targeted Therapies in NSCLC

EP: 6.Thoracic Oncologist Perspectives on a Rapidly Evolving Treatment Landscape

EP: 7.Identifying HER2 Mutations for T-DXd Use in NSCLC

(Rohit asks Levy) How do you interpret HER2 IHC scores when determining treatment for patients with NSCLC? How does this influence your therapeutic decisions?
When applying HER2 scoring and considering ASCO/CAP guidelines in NSCLC, do you follow breast cancer scoring guidelines, or have you considered using gastric cancer scoring?
How do you interpret equivocal or borderline results? Are there any specific considerations or additional testing you recommend for this group?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!